With each passing year, insurance companies are instituting contractual clauses in benefit packages that restrict psychiatric medications for patients. Specifically, this comes in the form of prior authorization for stimulant medications, despite FDA approval of these medications for ADHD. Combine the prior authorization process with changes in drug formularies (a tiered ... Read More
Category: Patient Education
23
Jan2016
ADHD in adults has now been recognized by clinicians for many years now. However, ADHD in older adults has received almost no attention because research has limited its work to those people under the age of 50. There is a body of research developing in older adults and I recently ... Read More
January 23, 2016David W. Goodman, MD
20
Jan2016
Every year Shire sponsors scholarships for ADHD individuals who are seeking funds to continue their educational pursuits. I post this information for those who follow my blog and know someone in need. Pass this information on to them.
"If you have patients diagnosed with ADHD who are pursuing higher education, please ... Read More
January 20, 2016David W. Goodman, MD
14
Jan2016
National Public Radio will air an interview with Dr. David W. Goodman on Jan 18th Monday on "Morning Edition" 8am. In addition to Dr. Goodman, older adults will offer their insight on struggling with ADHD for their whole life and the transformation that occurred with an accurate diagnosis and effective treatment. ... Read More
January 14, 2016David W. Goodman, MD
29
Dec2015
American Professional Society for ADHD and Related Disorders has posted videos by many of the speakers at this year's conference. For those professionals and others who are interested in the covered topics, we can listen the 5 min videos descriptions by the speakers of their topics. My video about ADHD ... Read More
December 29, 2015David W. Goodman, MD
22
Dec2015
On December 16, 2015, our article reviewing the world’s English scientific literature on ADHD in adults over age 50 years was published online in Drugs and Aging, an international journal. While there is a paucity of research, there are enough publications to merit pulling this literature together into one paper. ... Read More
December 22, 2015David W. Goodman, MD
11
Dec2015
Vayarin is marketed as a “medical food” for the treatment of ADHD. Vayarin contains Phosphatidylserine 75 mg, Eicosapentaenoic acid (EPA) 21.5 mg, and Docosahexaenoic acid (DHA) 8.5 mg. These ingredients are omega3 fatty acids. The recommended dose is 4 pills daily.
The company sponsored a 15-week, double blind, placebo controlled trial ... Read More
December 11, 2015David W. Goodman, MD
04
Nov2015
Insurance companies and "health care coordinators" are increasingly insinuating themselves into the care of patients. While we are all accustom to generic substitutions as a cost saving measure, you may not be aware that a pharmacist of CareFirst is "working with primary care physicians" to review cost effective medication treatments ... Read More
November 4, 2015David W. Goodman, MD
13
Oct2015
On September 30, 2015, The New York Times ran an article in the Tuesday Science section on ADHD in older adults. I was interviewed for the article and discussed a former patient age 73 who was first diagnosis with ADHD by me and successfully treated. The article is an introduction ... Read More
October 13, 2015David W. Goodman, MD
20
Apr2015
In my periodic entries of insurance companies' denial of ADHD medication dosing, I offer you this recent example.
A female in her late 20s treated for ADHD with a combination of Adderall XR and Strattera. Strattera adds a benefit for her executive function not optimized with Adderall XR. I carefully dosed ... Read More
April 20, 2015David W. Goodman, MD